Kyowa Kirin Co., Ltd. (TYO: 4151)
Japan
· Delayed Price · Currency is JPY | Market Cap | 1.31T |
| Revenue (ttm) | 498.98B |
| Net Income (ttm) | 83.54B |
| Shares Out | 508.98M |
| EPS (ttm) | 156.73 |
| PE Ratio | 16.40 |
| Forward PE | 18.61 |
| Dividend | 58.00 (2.26%) |
| Ex-Dividend Date | Dec 27, 2024 |
| Volume | 1,352,400 |
| Open | 2,608.00 |
| Previous Close | 2,609.50 |
| Day's Range | 2,553.50 - 2,617.50 |
| 52-Week Range | 2,266.50 - 3,350.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 31, 2024 |
About Kyowa Kirin
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormon... [Read more]
Financial Performance
In 2023, Kyowa Kirin's revenue was 442.23 billion, an increase of 11.01% compared to the previous year's 398.37 billion. Earnings were 81.19 billion, an increase of 51.55%.
Financial StatementsNews
Kyowa Kirin 9M GAAP EPS of Yen 105.19, revenue of Yen 362.8B
Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company
TOKYO--(BUSINESS WIRE)--Japan-based Global Specialty Pharmaceutical Company Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto.) (TOKYO:4151) today announced that Masashi Miyamoto, Ph.D. will ...
Kyowa Kirin Announces Positive Interim Real-world Data for Mogamulizumab (Poteligeo®) in Cutaneous T-cell Lymphoma at EORTC-CLTG 2024
GALASHIELS & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced it will present interim find...
Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 ROCKET HORIZON Trial for Adults with Moderate to Severe Atopic Dermatitis
Rocatinlimab Met Co-Primary Endpoints of vIGA-ADTM 0/1 with a ≥ 2-Point Reduction from Baseline, EASI-75, and All Key Secondary Endpoints HORIZON is the First of Eight Phase 3 Trials in the ROCKET Pro...
Kyowa Kirin to Present New Research Spotlighting Global Efforts to Advance Science and Patient Care in X-linked Hypophosphatemia at ASBMR Annual Meeting
One oral presentation and nine posters will shed light on real-world experiences of people living with XLH and the impact of burosumab treatment TOKYO , Sept. 19, 2024 /PRNewswire/ -- Kyowa Kirin Co.,...
New Analysis Demonstrates Impaired Work Productivity and Increased Unemployment Rates in Adults with X-linked Hypophosphataemia (XLH)
Findings from XLH Disease Monitoring Program (DMP) published in Journal of Bone and Mineral Research The DMP is a global effort, supported by Kyowa Kirin, to advance scientific understanding and care ...
Kyowa Kirin to end distribution of Fareston (toremefine) in the United States
PRINCETON, N.J., Aug. 23, 2024 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd.
Kyowa Kirin International and NewBridge Pharmaceuticals Enter Into Agreement to Improve Access to Medicines for Rare Disease Patients Across Middle East and North Africa
GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin) and a Japan-based global specialty ...
Kyowa Kirin Announces Board Approval for Construction of New Biologics Manufacturing Plant in Sanford, NC
Company's first manufacturing facility in North America to accelerate production of new biologic therapies to advance clinical pipeline Facility to draw upon local talent, area colleges and universiti...
Kyowa Kirin Will Present Pre-Clinical Data at the Association for Research in Vision and Ophthalmology Annual Meeting 2024
PRINCETON, N.J. and TOKYO , May 8, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd.
Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ® (istradefylline) and Other Parkinson's Disease Add-On Therapies
PRINCETON, N.J., April 12, 2024 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, will announ...
Kyowa Kirin Announces Acceptance of Abstract for Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 2024
PRINCETON, N.J. and TOKYO , April 2, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd.
Kyowa Kirin's gene therapy most expensive US drug with $4.3 mln price tag
Orchard Therapeutics, a unit of Japan's Kyowa Kirin , priced its newly approved gene therapy for a rare, life-threatening genetic disease on Wednesday at $4.25 million, making it the most expensive dr...
Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024
PRINCETON, N.J. and TOKYO , March 8, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd.
Kyowa Kirin Announce Symposium, Acceptance of Abstract for Presentation at American Academy of Dermatology 2024 Meeting
PRINCETON, N.J. and TOKYO , Feb. 14, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd.
Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema
TOKYO , Feb. 6, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced the enrollment of the first patient in a Phase 2 clinical trial, multi-center, randomized, double-masked, paralle...
Kyowa Kirin Responds to NICE's Publication of Appraisal Consultation Document for CRYSVITA® (Burosumab), for Treatment of Rare Disease X-Linked Hypophosphataemia (XLH) in Adults1
LONDON--(BUSINESS WIRE)--Adults living with the rare disease X-linked hypophosphataemia (XLH) in England and Wales risk missing out on an innovative treatment following an initial decision by NICE not...
Kyowa Kirin Presents Real-World Findings at ASBMR Annual Meeting Highlighting Progressive Disease Burden of X-linked Hypophosphatemia (XLH)
Claims database analyses show increasing prevalence and impact of XLH-related morbidities with age, underscoring life-long burden of disease PRINCETON, N.J. , Oct. 16, 2023 /PRNewswire/ -- Kyowa Kirin...
Kyowa Kirin to Present New Research on X-linked Hypophosphatemia (XLH) at ASBMR Annual Meeting
Five poster presentations provide greater understanding of patient profiles and real-world experiences of people living with XLH PRINCETON, N.J. , Oct. 12, 2023 /PRNewswire/ -- Kyowa Kirin, Inc., an a...
Kyowa Kirin Announces Three Abstracts and A Symposium at the European Academy of Dermatology and Venereology Congress 2023
TOKYO , Oct. 11, 2023 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083), an investigational produc...
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln
Japanese pharmaceutical firm Kyowa Kirin said on Thursday it would acquire Britain-based biopharmaceutical company Orchard Therapeutics for $477.6 million, aiming to promote the development of new dru...
Kyowa Kirin to Acquire Orchard Therapeutics
-Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases- -Acquisition enriches Kyowa Kirin's portfolio, enables th...
Kyowa Kirin Announces Acceptance for Presentations at the European Academy of Dermatology and Venereology Congress 2023
TOKYO , Oct. 4, 2023 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083), an investigational product being...
Kyowa Kirin: High-Risk High-Return Call Reiterating Our Buy Rating
Kyowa Kirin shares are viewed as a cheap option on the positive outcome for the atopic dermatitis drug being developed with Amgen. The company's recent track record for new drug trial success has been...
Kyowa Kirin Demonstrates Commitment to Real-world Evidence for POTELIGEO® (mogamulizumab) at EORTC 2023.
TOKYO--(BUSINESS WIRE)--Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced the acceptance of an extensive programme of data to the annual meeting of the...